An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ambrx Biopharma Inc. (NYSE: AMAM) announced that CEO Feng Tian will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on November 8, 2021, at 4:20 PM ET. The presentation will be accessible via a live webcast on the company's website, and a replay will be available for 90 days afterward. Ambrx focuses on Engineered Precision Biologics through an expanded genetic code platform, aiming to develop innovative therapies, including antibody drug conjugates and targeted immuno-oncology treatments.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on Monday, November 8th, 2021, at 4:20 PM ET.
A live webcast of the presentation will be available online in the “Investor Relations” section of the company’s website at https://ir.ambrx.com/events-and-presentations/events/default.aspx. A replay of the presentation will be available on the company website for 90 days following the webcast.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations, with multiple partners, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.
